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Abstract
Background
Associations between Vitamin D3 [25(OH)D], vitamin D binding protein (VDBP) and chronic
obstructive pulmonary disease (COPD) are previously reported. We aimed to further investi-
gate these associations on longitudinal outcomes.
Methods
426 COPD patients from western Norway, GOLD stage II-IV, aged 40–76, were followed
every six-month from 2006 through 2009 with spirometry, bioelectrical impedance measure-
ments and registration of exacerbation frequency. Serum 25(OH)D and VDBP levels were
determined at study-entry by high-performance liquid chromatography coupled with mass
spectrometry and enzyme immunoassays respectively. Yearly change in lung function and
body composition was assessed by generalized estimating equations (GEE), yearly exacer-
bation rate by negative binomial regression models, and 5 years all-cause mortality by Cox
proportional-hazard regression.
Results
1/3 of the patients had vitamin D deficiency (<20ng/mL) and a greater decline in both FEV1
and FVC, compared to patients with normal levels; for FEV1 this difference only reached statis-
tical significance in the 28 patients with the lowest levels (<10ng/mL, p = 0.01). Neither 25(OH)
D nor VDBP levels predicted exacerbation rate, change in fat free mass index or risk of death.
Conclusion
Severe vitamin D deficiency may affect decline in lung function parameters in COPD. Nei-
ther 25(OH)D nor VDBP levels did otherwise predict markers of disease progression.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and
mortality worldwide [1]. The progression of COPD varies greatly between afflicted subjects,
both in terms of lung function decline [2], exacerbation frequency [3], and development of co-
morbidities [4]. The reasons for this heterogeneity are largely unknown.
In cross-sectional studies, vitamin D deficiency (VDD) is common in COPD patients, and
has been associated with lower lung function both in COPD patients [5–7] and in the general
population [8]. Recently, a large longitudinal population based study found an association be-
tween lower plasma 25(OH)D levels with faster decline in lung function and a higher risk of
COPD [9]. There are plausible mechanisms by which vitamin D could impact COPD patho-
genesis, as the vitamin D receptor (VDR) is a nuclear transcription factor regulating the expres-
sion of more than 900 genes, many with immune functions [10]. Laboratory studies have
found associations between vitamin D and a strengthened innate immune response against air-
way infections by the production of antimicrobial peptides (AMPs) together with enhanced
macrophage phagocytic and chemotactic activity [11], improved lung development and lung
tissue repair [12, 13]. On the other hand, vitamin D may down-regulate inflammation through
decreased T-cell reactivity and pro-inflammatory response [14, 15]. Thus the impact of vitamin
D on the pulmonary inflammatory response is yet unclear.
Vitamin D binding protein (VDBP) is the main carrier of vitamin D metabolites, and gene
polymorphisms in the VDBP gene have been associated with COPD [5] and levels of 25(OH)D
[5, 16]. It has recently been suggested that low levels of 25(OH)D do not indicate true vitamin
D deficiency when levels of vitamin D binding protein also are low [16]. VDBP may also have
functions relevant to COPD progression independent of vitamin D carriage such as macro-
phage activation [17] and recruitment of neutrophils [18].
Thus, there is a rationale for examining the association of circulating levels of 25(OH)D and
VDBP on longitudinal COPD outcomes. To date, only the predictive value of circulating 25
(OH)D has been reported in a longitudinal setting; three studies have examined decline in lung
function, in which two were based on a general population [9, 19, 20], three studies assessed
the risk for acute exacerbations (AECOPD) [21–23], two studies have examined mortality
[22, 24], and none the decline in lean body mass, which is indicative of development of cachex-
ia. In addition, the results from these studies have been conflicting, possibly due to lack of ad-
justment for supplementation in some studies [19–21, 23, 24] and possibly due to a selected
study population, as some were post-hoc analyses from randomized trials on azithromycin in
COPD [21, 24].
The Bergen COPD Cohort Study is a well-described 3-year cohort study of COPD patients
and healthy controls from western Norway. The aim of the current study was to examine the
association of circulating 25(OH)D and VDBP on 5 years all-cause mortality, number of
AECOPD over three years, as well as change in lung function and lean body mass in COPD
patients.
Methods
Study population
The Bergen COPD Cohort Study (BCCS) was conducted between 2006 and early 2010. The cur-
rent study comprises 426 COPD patients enrolled in 2006, aged 40–76 years, and for whom vita-
min D3 [25(OH)D] were measured at baseline. The patients had a clinical diagnosis of COPD, a
smoking history of10 pack-years, and a post-bronchodilation FEV1/FVC ratio<0.7 and
FEV1<80% predicted. The patients were recruited during stable state, and active autoimmune
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diseases or cancer within the last 5 years were cause for exclusion. The sampling of the study
population in the BCCS and the data collection has been described in detail previously [6, 25].
All patients received written and oral information prior to inclusion, and provided signed
consent. The regional committee for medical and health research ethics, Western Norway, ap-
proved the study (study number 165.08).
Data sampling
A study physician examined all patients upon inclusion, and a structured interview regarding
smoking habits, exacerbation history the last 12 months, respiratory symptoms, general medi-
cal history, and medication use was undertaken.
All patients performed spirometry after inhalation of 0.4 mg salbutamol, on a Viasys Mas-
terscope (Viasys, Hoechberg, Germany).
Body composition was examined with bioelectrical impedance measurements in fasting
state, with a Bodystat 1500 (Bodystat Ltd, Douglas, Isle of Man, UK). Fat free mass index
(FFMI) was calculated as fat free mass in kilograms divided by the square of height in meters
(kg/m2), and similarly fat mass index was calculated as fat mass (kg) divided by height squared
(m2). Patients were classified as cachectic if FFMI<14 in women or<17 in men [26], or obese
if FMI>13.5 in women or>9.3 in men [27]. Measurements were not performed in two pa-
tients due to non-consent, and not in a patient who had a pacemaker.
Laboratory measurements
Peripheral venous blood was attempted sampled from all patients at baseline. Serum samples
were coagulated at room temperature for 30–45 minutes, followed by centrifugation at 2500 x
g for 15 minutes at 4°C. The serum was aliquoted and stored at −80°C in ultrafreezers.
A liquid chromatography double mass spectrometry (LC-MS/MS) [28] was used on serum
never previously thawed to measure 25(OH)D, as described in detail previously [6]. The mea-
surements of VDBP were performed on the same serum samples, during second thawing, by
enzyme immunoassay (R&D systems, Stillwater, MN, USA). Intra- and inter- assay coefficients
of variation were<10%.
Missing values
For 2 patients we lacked serum for VDBP analyses, thus measurements of this parameter were
available for 424 of the 426 patients. 29 patients only participated in the baseline visit. Among
reasons for discontinuation were use of oral steroids, lung cancer revealed by early CT scans,
withdrawal of consent and decease before any follow-up visits were performed. Thus, 426 pa-
tients were included in analyses on mortality, and 397 in analyses on later exacerbations, longi-
tudinal change in lung function and body composition. For the other baseline variables there
were no missing values.
Outcome variables
For the subsequent three years follow-up, patients were invited to visits every 6 months. At all
visits post-bronchodilation spirometry was performed. The study physician interviewed the
patients at all visits, collecting a detailed history of COPD exacerbations since last visit with the
aid of the patients' journal. The majority of patients were affiliated to our hospital; admission
to our hospital was registered. Also, patients were instructed to contact the study-staff at peri-
ods at worsening of symptoms by a cell phone, and were offered a clinical examination by the
study physician at the outpatient clinic, Dept. of Thoracic Medicine within 24 hours of contact,
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all of which would be recorded in the patients' journal. All exacerbations requiring treatment
with either oral steroids or antibiotics were recorded during follow-up, and were included in
the analyses. Bioelectrical impedance was measured yearly.
All citizens in Norway have a unique identification number given by birth, and all deaths
are recorded in national registers that are linked to the electronic patient journals. After study
completion, on the 25th of August 2011, the patients' records were screened for mortality. Date
of death was recorded if applicable, whereas cause of death was not available for the current
analyses.
Statistical analyses
Whereas 25(OH)D had a normal distribution, the VDBP had an upper detection level of 500μg/
mL, where higher levels were simply classified as higher (n = 2). Thus, non-parametric tests
were applied to VDBP when examined as an outcome. A cut-off level of<20ng/mL, was used to
define vitamin D deficiency (VDD). In addition sub-categories; less severe (10–20ng/mL) and
severe deficiency (<10ng/mL) was used in analyses. VDBP was categorized in three categories
and the ratio between 25(OH)D and VDBP was categorized in quartiles. Differences between
patients with normal or deficient vitamin D levels, and low, medium or high levels of VDBP
were examined with chi-square tests, t-tests or ANOVA.
For all-cause mortality, a Cox proportional-hazard model was fitted. A negative binomial
regression model was used for analyses of annual exacerbation rate due to between-subject var-
iation (overdispersion) [29] and the model was extended for panel data and allowed random
effects to capture within subject associations over the time periods. The effects of 25(OH)D,
VDBP and quartiles of their ratio on mean yearly change in FEV1, FVC and FFMI were investi-
gated by generalized estimating equations (GEE) models [30] by including the outcome vari-
ables by time interaction and adjusting for baseline season, use of vitamin D supplements, sex,
age, smoking, body composition, GOLD stage, and number of exacerbations (>2; yes or no)
the last year before baseline. The mean number of FEV1 and FVC measurements included in
the GEE models was 6 per subject, and for FFMI 3.7 per subject.
All analyses were performed with Stata version 13.1 (Statacorp LP, College Station, TX,
USA).
Results
COPD patients with VDD (<20ng/mL, n = 142) were more often current smokers, had more
severe COPD, were more likely to be frequent exacerbators, and were more often either cachec-
tic or obese compared to patients with non-deficient levels (n = 284) (Table 1). Female COPD
patients were more likely to have higher levels of VDBP (p = 0.05), otherwise associations be-
tween VDBP and clinical characteristics were non-significant (Table 1).
A scatterplot of measured 25(OH)D and VDBP is presented in Fig. 1, and shows a low cor-
relation between 25(OH)D and VDBP.
Thus, some patients with for instance low levels of 25(OH)D will have quite low levels of
VDBP and therefore possibly a normal bioavailability of 25(OH)D, whereas other patients
with low levels of 25(OH)D and high levels of VDBP could theoretically have a lower bioavail-
ability of 25(OH)D.
During a follow-up time of 5 years, 69 patients out of 426 were deceased. 25(OH)D or
VDBP levels at baseline in patients that died did not differ from patients still alive, generating
non-significant hazard ratios and no predictive value of either 25(OH)D, VDBP or the ratio of
25(OH)D to VDBP on risk of death (Table 2).
There was a wide variety in exacerbation frequency, and its distribution is shown in Fig. 2.
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Neither 25(OH)D nor VDBP levels or the ratio between 25(OH)D and VDBP were signifi-
cant predictors of subsequent moderate or severe COPD exacerbations, where the incidence
rate ratios approached 1 for most all categories regardless of adjustment (Table 3).
Examining the effects of vitamin D deficiency on later change in lung function, it was found
that COPD patients with vitamin D deficiency had a greater decline in both FEV1 and FVC per
year, compared to patients with normal levels of 25(OH)D; both in the model only adjusted for
season and supplements as well as in the fully adjusted model (Table 4). Vitamin DBP levels
did not show any significant associations with change in either FEV1 or FVC (Table 4). COPD
patients with smaller 25(OH)D/VDBP ratio had greater declines in FEV1, however only statis-
tically significant for the second and third quartile, and not in the fully adjusted model.
To better show the meaning of the coefficients presented in Table 4, we graphed the estimat-
ed yearly change in lung function for patients with different levels of measured 25(OH)D at
baseline, calculated from the coefficients from the multivariable regression analyses (Fig. 3).
Specifically, COPD patients with the lowest levels (<10ng/mL) of 25(OH)D had the largest
decline in both FVC and FEV1 in percent predicted, whereas patients with intermediate defi-
ciency (10–20ng/mL) also had significantly greater declines than patients without VDD.
Table 1. Baseline characteristics of the COPD patients in the study sample categorized by measured levels of serum vitamin D (25(OH)D) and Vita-
min D binding protein (VDBP).
25(OH)D > 20 ng/
mL (n = 284)
25(OH)D < 20 ng/
mL (n = 142)
p* VDBP <200 μg/
mL (n = 138)
VDBP 200–
299 μg/mL
(n = 240)
VDBP  300 μg/mL
(n = 46)
p**
Sex, % 0.73 0.05
Women 40.5 38.7 37.2 37.7 59.1
Men 59.5 61.3 62.8 62.3 40.9
Age, mean (SD) 63.9 (6.8) 62.8 (7.0) 0.13 63.9 (7.4) 63.4 (6.8) 62.7 (5.9) 0.54
Smoking, % <0.01 0.78
Ex 61.3 45.8 53.6 56.7 58.7
Current 38.7 54.2 46.4 43.3 41.3
GOLD 2007 stage, % <0.01 0.80
II 56.0 27.5 44.2 46.7 54.4
III 36.3 53.5 42.8 42.1 37.0
IV 7.8 19.0 13.0 11.3 8.7
Number of exacerbations last
year before inclusion, %
0.02 0.12
0–1 85.6 76.8 83.3 84.2 71.7
2+ 14.4 23.2 16.7 15.8 28.3
Body composition, % <0.01 0.98
Normal 61.3 46.5 55.8 57.1 54.4
Cachectic 26.8 31.7 29.7 27.1 30.4
Obese 12.0 21.8 14.5 15.8 15.2
Taking calcium & vitamin D
supplements, %
0.27 0.11
No 95.8 97.9 96.4 97.5 91.3
Yes 4.2 2.1 3.6 2.5 8.7
* ttest for age, chi square for all other variables
** ANOVA for age, chi square for all other variabels.
doi:10.1371/journal.pone.0121622.t001
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As shown in Table 5, neither levels of 25(OH)D nor levels of VDBP impacted later change
in FFMI, however there was a trend towards a smaller decline for the patients with the largest
25(OH)D/VDBP ratio (Table 5).
Discussion
In this longitudinal COPD cohort, in whom one third of the study sample had VDD, we were
unable to find a predictive value of 25(OH)D on exacerbation rate, change in body composition
or 5 years all-cause mortality. Meanwhile, we found a significant effect of deficient 25(OH)D
levels on change in lung function parameters FEV1 and FVC, most convincingly for FVC.
Alongside, VDBP was examined for the same outcomes but had no significant effect on neither
of them.
Our study results must be interpreted within the limitations of having one single measure-
ment of 25(OH)D, that only moderate to severe exacerbations were recorded, that only a small
subgroup of patients (n = 28) had 25(OH)D levels<10ng/mL, and that we did not have data
on gene polymorphisms in the VDBP gene. Also, the use of 25(OH)D as a substrate for vitamin
D status may be less sensitive as it do not necessarily reflect local bioavailability/metabolism, as
1,25(OH)D would.
However, the strengths of this study includes adjustments for supplements, use of liquid
chromatography double mass spectrometry for the measurement of 25(OH)D, the comprehen-
sive follow-up of the study sample, and the hitherto unexamined potential influence of VDBP.
Fig 1. Scatterplot of measured 25(OH)D and Vitamin D binding protein in 426 and 424 COPD patients respectively.
doi:10.1371/journal.pone.0121622.g001
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Table 2. Predictive value of levels of 25(OH)D and Vitamin D binding protein on 5 years all-causemortality (69 events) in 426* COPD patients (Haz-
ard ratios with 95% confidence intervals).
Adjusted only for season and supplements Adjusted for season, supplements, sex, age,
smoking, body composition, GOLD stage and
number of exacerbations the last year before
baseline
HR 95% CI p HR 95% CI p
Vitamin D
Per 10 ng/mL decrease 1.10 0.86, 1.41 0.46 0.95 0.71, 1.26 0.71
Deﬁciency
>20 ng/mL 1 1
10–20 ng/mL 1.62 0.94, 2.76 0.08 1.44 0.82, 2.55 0.21
<10 ng/mL 1.04 0.36, 2.94 0.95 0.80 0.26, 2.40 0.68
Vitamin DBP
0–199 μg/mL 1 1
200–299 μg/mL 0.88 0.53, 1.46 0.62 1.03 0.60, 1.75 0.93
300+ μg/mL 0.58 0.22, 1.54 0.27 0.76 0.28, 2.02 0.58
Vitamin D3/ DBP ratio
Q4 (largest) 1 1
Q3 1.01 0.51, 1.99 0.97 0.95 0.48, 1.90 0.89
Q2 1.22 0.64, 2.35 0.60 1.11 0.56, 2.19 0.76
Q1 (smallest) 0.86 0.40, 1.82 0.69 0.77 0.35, 1.68 0.51
* the analyses including vitamin DBP includes 424 COPD patients, of which 68 were later deceased.
doi:10.1371/journal.pone.0121622.t002
Fig 2. Total number of exacerbations during 3 years in 397 COPD patients.
doi:10.1371/journal.pone.0121622.g002
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25(OH)D and mortality
Two previous population-based studies [31, 32] (with a median of 3.1 and 8.7 years of follow-
up) have found higher mortality in subjects with very low 25(OH)D levels, a finding not repli-
cated in our study on COPD patients.
We can not exclude that the lack of association between 25(OH)D and mortality in our
study was due to lack of statistical strength. However, our results were in accordance with two
recent studies; one 10-year follow-up study on 426 COPD patients originally included in a ran-
domized trial with azithromycin [24] and another 2-year follow-up study on 356 COPD pa-
tients [22].
25(OH)D and exacerbation frequency
By modulating innate and adaptive immune responses, vitamin D may increase the production
of antimicrobial peptides and autophagy of macrophages [11, 33] and thereby strengthen the
host defense against infection. Clinical studies suggest an anti-infectious role of 25(OH)D in
patients with bronchiectasis, and upper respiratory infection [34, 35].
To our knowledge, three previous studies with longitudinal design [21–23] and one ran-
domized trial [36] have examined possible effects of 25(OH)D levels on infectious COPD exac-
erbations. These studies and our study report negative findings. One study was a secondary
analysis of a randomized trial in 993 patients at risk of exacerbation [21], follow-up between
the four studies varied between 1 to 3 years, and only one adjusted for supplements [22].
The mean number of exacerbations per patient-year in our study was identical to the aver-
age rate of 0.73 in the UPLIFT study [37] and slightly lower than the rates presented in the
TORCH study (0.85) and the ECLIPSE study (0.85–1.34) [2, 38]. Thus, the combination of a
high prevalence of vitamin D deficiency in our study population and a distribution of
Table 3. Predictive value of levels of 25(OH)D and Vitamin D binding protein on subsequent yearly exacerbation rate in the 397 COPD patients (In-
cidence rate ratio with 95% confidence intervals) for whomwe had follow-data on exacerbations.
Adjusted only for season and supplements Adjusted for season, supplements, sex, age,
smoking, body composition, GOLD stage and
number of exacerbations the last year before
baseline
IRR 95% CI p IRR 95% CI p
Vitamin D
Per 10 ng/mL decrease 1.05 0.93, 1.19 0.46 0.96 0.85, 1.08 0.47
Deﬁciency
>20 ng/mL 1 1
10–20 ng/mL 1.09 0.82, 1.45 0.56 0.92 0.70, 1.19 0.52
<10 ng/mL 1.42 0.89, 2.27 0.15 1.09 0.72, 1.66 0.69
Vitamin DBP
0–199 μg/mL 1 1
200–299 μg/mL 0.96 0.74, 1.25 0.76 1.02 0.81, 1.29 0.88
300+ μg/mL 0.92 0.61, 1.40 0.71 0.96 0.66, 1.39 0.82
Vitamin D3/ DBP ratio
Q4 (largest) 1 1
Q3 1.03 0.74, 1.46 0.85 1.04 0.77, 1.39 0.82
Q2 1.12 0.79, 1.58 0.53 1.10 0.81, 1.49 0.55
Q1 (smallest) 0.98 0.68, 1.41 0.92 0.81 0.59, 1.12 0.20
doi:10.1371/journal.pone.0121622.t003
Vitamin D and Vitamin D Binding Protein in COPD
PLOSONE | DOI:10.1371/journal.pone.0121622 March 24, 2015 8 / 14
T
ab
le
4.
P
re
d
ic
ti
ve
va
lu
e
o
fl
ev
el
s
o
f2
5(
O
H
)D
an
d
V
it
am
in
D
b
in
d
in
g
p
ro
te
in
o
n
ye
ar
ly
ch
an
g
e
in
lu
n
g
fu
n
ct
io
n
in
39
7
C
O
P
D
p
at
ie
n
ts
es
ti
m
at
ed
b
y
g
en
er
al
iz
ed
es
ti
m
at
in
g
eq
u
at
io
n
s
(G
E
E
).
A
d
ju
st
ed
o
n
ly
fo
r
se
as
o
n
an
d
su
p
p
le
m
en
ts
A
d
ju
st
ed
fo
r
se
as
o
n
,s
u
p
p
le
m
en
ts
,s
ex
,a
g
e,
sm
o
ki
n
g
,b
o
d
y
co
m
p
o
si
tio
n
,G
O
L
D
st
ag
e
an
d
n
u
m
b
er
o
f
ex
ac
er
b
at
io
n
s
th
e
la
st
ye
ar
b
ef
o
re
b
as
el
in
e
ye
ar
ly
ch
an
g
e
in
F
E
V
1
in
%
p
re
d
ic
te
d
p
ye
ar
ly
ch
an
g
e
in
F
V
C
in
%
p
re
d
ic
te
d
p
ye
ar
ly
ch
an
g
e
in
F
E
V
1
in
%
p
re
d
ic
te
d
p
ye
ar
ly
ch
an
g
e
in
F
V
C
in
%
p
re
d
ic
te
d
p
V
ita
m
in
D
P
er
10
ng
/m
L
de
cr
ea
se
−
0.
10
7
0.
28
−
0.
35
6
0.
03
−
1.
05
0.
26
−
0.
35
2
0.
02
D
eﬁ
ci
en
cy
>
20
ng
/m
L
−
0.
89
4
−
1.
53
8
−
0.
89
8
−
1.
54
7
10
–
20
ng
/m
L
−
1.
30
3
0.
07
−
2.
75
7
0.
00
1
−
1.
27
4
0.
07
−
2.
74
7
0.
00
1
<
10
ng
/m
L
−
1.
86
9
0.
02
−
3.
27
5
0.
01
−
1.
88
5
0.
01
−
3.
28
9
0.
01
V
ita
m
in
D
B
P
0–
19
9
μ
g/
m
L
−
0.
85
3
−
1.
81
3
−
0.
85
3
−
1.
81
8
20
0–
29
9
μ
g/
m
L
−
1.
16
2
0.
16
−
2.
20
4
0.
52
−
1.
16
3
0.
13
−
2.
20
5
0.
49
30
0+
μ
g/
m
L
−
1.
05
8
0.
55
−
1.
66
2
0.
78
−
1.
04
9
0.
54
−
1.
65
8
0.
76
V
ita
m
in
D
3/
D
B
P
ra
tio
Q
4
(la
rg
es
t)
−
0.
70
6
−
1.
55
2
−
0.
70
9
−
1.
55
7
Q
3
−
1.
22
8
0.
04
−
1.
62
1
0.
87
−
1.
22
4
0.
03
−
1.
61
8
0.
89
Q
2
−
1.
28
4
0.
04
−
2.
36
5
0.
07
−
1.
28
6
0.
03
−
2.
38
1
0.
06
Q
1
(s
m
al
le
st
)
−
1.
17
4
0.
10
−
2.
30
1
0.
08
−
1.
17
0
0.
08
−
2.
30
0
0.
08
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
21
62
2.
t0
04
Vitamin D and Vitamin D Binding Protein in COPD
PLOSONE | DOI:10.1371/journal.pone.0121622 March 24, 2015 9 / 14
exacerbation frequencies representative for COPD patients in general, we believe, should gen-
erate statistical power enough to capture differences of clinical importance.
25(OH)D and lung function
A positive association between lung function and levels of 25(OH)D has been demonstrated in
large population-based cross-sectional [8] and longitudinal studies [9]. This was also repro-
duced in cross-sectional studies on COPD that found an association between FEV1, FVC and
25(OH)D [7], or with FEV1 and 25(OH)D only [5, 6]. There have been few longitudinal studies
to date on VDD and change in lung function. Kunisaki et al. followed 196 continuous smokers
with COPD during 6 years and found no difference in baseline 25(OH)D levels between pa-
tients with rapid and slow decline in FEV1 [19]. This is in contrast to findings in a large popula-
tion-based study where lower 25(OH)D levels was associated with faster decline in FEV1 in
1647 COPD patients [9]. Moreover, in a community-based sample of 626 elderly men followed
for 20 years, the combination of current smoking and VDD was significantly associated with a
faster decline in FEV1 [20]. Different from Afzal et al [9], we found a greater decline in both
FVC and FEV1 per year in patients with severe VDD (<10ng/mL) compared to patients with
normal levels. Similar observations were made for FVC (and with borderline significance for
FEV1) in patients with less severe VDD (10–20ng/mL). Unsurprisingly, yearly change in the
FEV1/FVC ratio was indifferent to 25(OH)D levels when examined in the same statistical
model used in separate analyses on FEV1 and FVC (data not shown).
Vitamin D deficiency was more common in current smokers at baseline in our study sam-
ple. However, a post-hoc analysis, including an interaction term with 25(OH)D and smoking
Fig 3. Yearly estimated change in FVC and FEV1 in percent predicted by levels of measured vitamin D
at baseline.
doi:10.1371/journal.pone.0121622.g003
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status, did not support previous findings [20], indicating effect modification of smoking on as-
sociations between 25(OH)D and lung function.
25(OH)D and body composition
The adverse event of a disproportional loss of fat-free mass, cachexia, is common, depicts
higher risk for morbidity and mortality in COPD, and has been linked to increased systemic in-
flammation [4]. Vitamin D supplements have been shown to have a positive effect on lower-ex-
tremity function, muscle strength and balance in elderly [39] and higher levels of vitamin D
have been associated with increased exercise capacity in COPD patients in a cross-sectional
study [7]. Meanwhile, our data suggested no association between 25(OH)D and loss of fat free
mass in this COPD population. Several other mechanisms are likely of greater importance than
25(OH)D considering the complexity of a cachectic condition. Our data does not exclude a
possible association of 25(OH)D on muscle weakness or physical endurance in COPD; these is-
sues should be addressed in future research.
Vitamin D binding protein (VDBP)
Effects of VDBP were investigated on the same outcomes as for 25(OH)D, both as an indepen-
dent factor and as a co-factor to vitamin D with the 25(OH)D/VDBP ratio. We calculated the
25(OH)D/VDBP ratio to theorize a substrate for bioavailable 25(OH)D, as total 25(OH)D lev-
els may be impacted by the concentrations of VDBP [16]. However, taking VDBP into account
when assessing VDD did not seem to add vital information to the status or effect of VDD in
Table 5. Predictive value of levels of Vitamin D3 (25OH) and Vitamin D binding protein on yearly change in fat free mass index (FFMI) in 397 COPD
patients estimated by generalized estimating equations (GEE).
Adjusted only for season and supplements Adjusted for season, supplements, sex, age,
smoking, body composition, GOLD stage and
number of exacerbations the last year before
baseline
yearly change in fat free mass index (FFMI) p yearly change in fat free mass index (FFMI) p
Vitamin D
Per 10 ng/mL decrease −0.026 0.22 −0.025 0.16
Deﬁciency
>20 ng/mL −0.043 −0.044
10–20 ng/mL −0.108 0.18 −0.109 0.12
<10 ng/mL −0.025 0.84 −0.031 0.86
Vitamin DBP
0–199 ug/mL −0.086 −0.088
200–299 ug/mL −0.030 0.22 −0.031 0.14
300+ ug/mL −0.054 0.65 −0.056 0.60
Vitamin D3/ DBP ratio
Q4 (largest) −0.012 −0.013
Q3 −0.024 0.83 −0.026 0.78
Q2 −0.120 0.06 −0.119 0.03
Q1 (smallest) −0.068 0.32 −0.069 0.25
doi:10.1371/journal.pone.0121622.t005
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our study sample. Adding VDBP as a potential confounder in all multivariable regression mod-
els did not alter any effects of 25(OH)D, supporting this finding (data not shown).
We also hypothesized that functions of VDBP independent from 25(OH)D carriage may in-
fluence COPD progression, based on previous studies where VDBP was found to activate alve-
olar macrophages in sputum [17] and induce recruitment of neutrophils by increasing
chemotactic activity of the complement peptide C5a [18]. Also, in cross-sectional data, higher
systemic levels of VDBP have been associated with lower FEV1 in COPD patients [17], and
higher sputum levels have been linked to increased airway inflammation and exacerbation fre-
quency in patients with bronchiectasis followed for 3 years [34]. However these findings were
not supported in our data. Likewise, VDBP showed no significant effect on mortality or change
in body composition.
We were restricted by having serum VDBP levels only and are therefore unable to discuss
the impact of local VDBP levels (sputum) on airway inflammation. The relationship between
VDBP and COPD is previously described on the basis of gene polymorphisms in VDBP genes
(GC) that show association with increased risk of COPD [5, 40] and low levels of 25(OH)D [5].
In our data, we cannot exclude a possible effect of different gene combination on
outcomes examined.
In conclusion, we used the gold standard method to measure 25(OH)D levels and found
that severe vitamin D deficiency predicted later decline in lung function in COPD patients, an
important parameter of COPD disease progression.
25(OH)D or VDBP levels did otherwise not predict markers of disease progression. This
may imply that the effects of vitamin D in COPD disease progression are so small as to be clini-
cally less relevant, or that vitamin D deficiency is a later event rather than a potentially
causal factor.
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